Atyr PHARMA (ATYR) News Today $3.35 +0.20 (+6.35%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period iTeos Therapeutics price target lowered to $19 from $31 at Wells FargoDecember 20 at 8:27 AM | finance.yahoo.comaTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%December 19 at 9:44 PM | finance.yahoo.comaTyr Pharma appoints Eric Benevich to the company’s BoardDecember 13, 2024 | markets.businessinsider.comaTyr Pharma Announces the Appointment of Eric Benevich to its Board of DirectorsDecember 12, 2024 | globenewswire.comHC Wainwright Reiterates "Buy" Rating for Atyr PHARMA (NASDAQ:ATYR)December 12, 2024 | americanbankingnews.comPositive Outlook for aTyr Pharma: Favorable Phase 3 Progress and Competitive Advantage Highlight Buy RatingDecember 12, 2024 | markets.businessinsider.comaTyr Pharma: Promising Clinical Developments and Strategic Trial Design Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comaTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisDecember 10, 2024 | markets.businessinsider.comaTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on FibrosisDecember 9, 2024 | globenewswire.comaTyr Pharma’s Strategic Advantage and Promising Developments in Pulmonary Sarcoidosis TreatmentDecember 5, 2024 | markets.businessinsider.comStrategic Advantages in aTyr Pharma’s Clinical Trials Highlighted in Analyst’s Buy RatingDecember 5, 2024 | markets.businessinsider.comaTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on FibrosisNovember 15, 2024 | globenewswire.comAtyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 55.1% in OctoberAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,660,000 shares, an increase of 55.1% from the October 15th total of 1,070,000 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 761,100 shares, the short-interest ratio is currently 2.2 days.November 14, 2024 | marketbeat.comaTyr Pharma Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comaTyr Pharma Positioned for Success with Strong Financials and Pivotal Trial ResultsNovember 9, 2024 | markets.businessinsider.comAtyr PHARMA (NASDAQ:ATYR) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday.October 29, 2024 | marketbeat.comShort Interest in Atyr PHARMA INC (NASDAQ:ATYR) Drops By 21.3%Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,070,000 shares, a decline of 21.3% from the September 30th total of 1,360,000 shares. Approximately 1.5% of the company's stock are sold short. Based on an average daily volume of 684,000 shares, the days-to-cover ratio is currently 1.6 days.October 28, 2024 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Sees Significant Growth in Short InterestAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,360,000 shares, an increase of 98.3% from the September 15th total of 685,800 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily trading volume, of 443,700 shares, the short-interest ratio is currently 3.1 days.October 11, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and aTyr Pharma (ATYR)October 6, 2024 | markets.businessinsider.comaTyr Pharma, Inc. (ATYR) Stock Historical Prices & Data - Yahoo FinanceOctober 5, 2024 | ca.finance.yahoo.comWells Fargo Initiates Coverage of aTyr Pharma (ATYR) with Overweight RecommendationOctober 5, 2024 | msn.comAtyr PHARMA (NASDAQ:ATYR) Coverage Initiated at Wells Fargo & CompanyWells Fargo & Company began coverage on shares of Atyr PHARMA in a research note on Friday. They issued an "overweight" rating and a $17.00 price target on the stock.October 4, 2024 | marketbeat.comaTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory JournalOctober 2, 2024 | finance.yahoo.comShort Interest in Atyr PHARMA INC (NASDAQ:ATYR) Rises By 55.5%Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 685,800 shares, an increase of 55.5% from the August 31st total of 440,900 shares. Approximately 0.9% of the company's stock are sold short. Based on an average trading volume of 371,400 shares, the days-to-cover ratio is presently 1.8 days.September 27, 2024 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 27.1% in AugustAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 440,900 shares, an increase of 27.1% from the August 15th total of 346,800 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 387,800 shares, the days-to-cover ratio is presently 1.1 days.September 14, 2024 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Sees Large Growth in Short InterestAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a significant increase in short interest in August. As of August 15th, there was short interest totalling 346,800 shares, an increase of 28.2% from the July 31st total of 270,600 shares. Based on an average trading volume of 384,700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.5% of the company's shares are short sold.August 30, 2024 | marketbeat.comaTyr Pharma to Participate in September Investor ConferencesAugust 21, 2024 | globenewswire.comaTyr Pharma, Inc. (ATYR)August 18, 2024 | uk.finance.yahoo.comAtyr PHARMA INC (NASDAQ:ATYR) Sees Large Decline in Short InterestAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large decline in short interest in July. As of July 31st, there was short interest totalling 270,600 shares, a decline of 19.6% from the July 15th total of 336,600 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 451,500 shares, the days-to-cover ratio is currently 0.6 days.August 17, 2024 | marketbeat.comQ3 2024 Earnings Estimate for Atyr PHARMA INC Issued By HC Wainwright (NASDAQ:ATYR)Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Research analysts at HC Wainwright increased their Q3 2024 earnings per share estimates for shares of Atyr PHARMA in a report released on Wednesday, August 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings peAugust 16, 2024 | marketbeat.comIs aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?August 15, 2024 | finance.yahoo.comAtyr PHARMA (NASDAQ:ATYR) Given "Outperform" Rating at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $16.00 price target on shares of Atyr PHARMA in a research note on Wednesday.August 14, 2024 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPSAtyr PHARMA (NASDAQ:ATYR - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01.August 14, 2024 | marketbeat.comaTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate UpdateAugust 13, 2024 | globenewswire.comAtyr PHARMA (NASDAQ:ATYR) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Thursday.August 1, 2024 | marketbeat.comaTyr Pharma’s Strategic Advances in Clinical Research Bolster Buy RatingAugust 1, 2024 | markets.businessinsider.comAtyr PHARMA INC (NASDAQ:ATYR) Director Purchases $100,939.00 in StockJuly 25, 2024 | insidertrades.comAtyr PHARMA INC (NASDAQ:ATYR) Director Paul Schimmel Purchases 41,052 SharesJuly 25, 2024 | insidertrades.com Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. ATYR Media Mentions By Week ATYR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATYR News Sentiment▼0.590.61▲Average Medical News Sentiment ATYR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATYR Articles This Week▼21▲ATYR Articles Average Week Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Collegium Pharmaceutical News Septerna News Bicara Therapeutics News Zymeworks News Gyre Therapeutics News Poseida Therapeutics News Phibro Animal Health News Cogent Biosciences News Nuvation Bio News ArriVent BioPharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATYR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atyr PHARMA INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Atyr PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
